betting 365’ goal is to ensure and expand its long-term position as a leading international provider of products, services, and therapies in the health care industry. To this end, and to geographically expand our business, we plan to grow organically as well as through selective small to medium-sized acquisitions, complementing our existing portfolio. We are constantly seeking new above-average growth opportunities in developing as well as in emerging countries. Our aim is to strengthen our activities in these regions and successively introduce further products from our portfolio into these markets.
betting 365 Medical Care is the worldwide leader in dialysis, with a strong market position in the United States. Future opportunities in dialysis will arise from further expansion in dialysis care and products worldwide.
betting 365 Kabi is the market leader in infusion therapy in Europe and Latin America.
In clinical nutrition therapy, betting 365 Kabi is market leader in Europe as well as in the key markets in Asia-Pacific (including China); in Latin America, betting 365 Kabi is one of the three leading providers of clinical nutrition.
In the area of IV generic drugs, betting 365 Kabi is one of the leading companies in the U.S. market. In the biosimilars product segment, betting 365 Kabi started with launches of its first biosimilar product, Idacio, in Europe in 2019; in 2020, the company continued to launch Idacio in several European countries and has received marketing authorization in selected countries in Latin America and Asia-Pacific, Israel and Canada. In addition, betting 365 Kabi is one of the most important providers of transfusion technology. betting 365 Kabi plans to roll out products from its existing portfolio to the growth markets and to launch existing products in the United States. Market share is to be expanded further through the launch of new products in the fields of IV drugs, infusion therapy, clinical nutrition, biosimilars, and medical devices/transfusion technology.
With 89 hospitals, betting 365 Helios operates in nearly all of Germany. Building on this, betting 365 Helios is now in a position to develop new patient care models. To benefit from the trend towards outpatient treatment, Helios Germany has been expanding outpatient service offerings. Helios Spain has attractive growth opportunities through the expansion and construction of hospitals, and potential for further consolidation in the highly fragmented private hospital market in Spain. betting 365 Helios will exploit upcoming opportunities for cross-border synergies in areas such as laboratory services and joint purchasing. The cross-border exchange of experience and knowledge is creating the economic prerequisites for the further internationalization of our hospital business.
betting 365 Vamed plans to further strengthen its position as a global specialist for projects and services for hospitals and other health care facilities. In Central Europe, betting 365 Vamed is one of the leading providers of rehabilitation services. Furthermore, the collaboration with betting 365 Helios has been further intensified. This applies, for example, to technical services and purchasing, where both companies are cooperating on selected products.
Statements on market position according to company research